{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004142","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.602679+00:00","generated_at":"2026-05-28T05:45:06.226415+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NewAmsterdam provides 2024-2025 update: Phase 3 data, $835M cash, EMA filing in 2H25","bullets":["BROADWAY Phase 3 met primary endpoint: 33% LS mean LDL-C reduction (p<0.0001); exploratory MACE reduction of 21%.","Unaudited year-end cash of $835 million; funds operations through PREVAIL CVOT readout and potential commercial launch.","Menarini to submit EMA filing for obicetrapib in 2H2025; additional Phase 3 data presentations planned throughout 2025.","VINCENT Phase 2 trial exploring obicetrapib +/- PCSK9i on Lp(a) expected to complete in 2H2025.","USPTO issued composition-of-matter patent for obicetrapib, providing IP protection in US until July 2043."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004142","json":"https://secwatch.observer/filing/0001193125-25-004142.json","markdown":"https://secwatch.observer/filing/0001193125-25-004142.md","text":"https://secwatch.observer/filing/0001193125-25-004142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525004142/0001193125-25-004142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525004142/d837783d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:45:06.226415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}